Avatrombopag

Definition

An orally available platelet thrombopoietin receptor (TPOR; MPL) agonist, with potential megakaryopoiesis stimulating activity. Upon administration, avatrombopag binds to and stimulates TPOR, which may lead to the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells. This increases the production of platelets and may prevent chemotherapy-induced thrombocytopenia (CIT). TPOR is a cytokine receptor and member of the hematopoietin receptor superfamily.

Also known as 4-Piperidinecarboxylic Acid, 1-(3-Chloro-5-(((4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl)amino)carbonyl)-2-pyridinyl)-, AKR 501, AKR-501, AKR501, AS 1670542, AVATROMBOPAG, Doptelet, E 5501, E-5501, E5501, YM 477, YM-477, YM477 — per NCIT

Also identified as

• ATC B02BX08 per RXNORM
• NCIT NCIT:C150559 per NCIT
• SCTID 770717002 per RXNORM
• SCTID 771571004 per RXNORM
• UNII 3H8GSZ4SQL per RXNORM

Indications